肺动脉高压中的种族和民族差异。
Racial and ethnic differences in pulmonary arterial hypertension.
作者信息
Al-Naamani Nadine, Paulus Jessica K, Roberts Kari E, Pauciulo Michael W, Lutz Katie, Nichols William C, Kawut Steven M
机构信息
1 14640 Pulmonary, Allergy and Critical Care Division, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, PA, USA.
2 Institute for Clinical Research and Health Policy Studies, Department of Medicine, Tufts Medical Center, Boston, MA, USA.
出版信息
Pulm Circ. 2017 Oct-Dec;7(4):793-796. doi: 10.1177/2045893217732213. Epub 2017 Sep 15.
Abstract
This study explores the racial and ethnic differences in presentation, severity, and treatment of patients with pulmonary arterial hypertension (PAH) in a large multicenter registry. African American and Hispanic patients are more likely to present with associated PAH compared to non-Hispanic whites. Hispanic patients with PAH were less likely to be treated with PAH-specific medications compared to non-Hispanic whites.
摘要
本研究在一个大型多中心登记处中，探讨了肺动脉高压（PAH）患者在临床表现、严重程度及治疗方面的种族和民族差异。与非西班牙裔白人相比，非裔美国人和西班牙裔患者更易出现相关PAH。与非西班牙裔白人相比，患有PAH的西班牙裔患者接受PAH特异性药物治疗的可能性较小。
相似文献
1
Racial and ethnic differences in pulmonary arterial hypertension.肺动脉高压中的种族和民族差异。
Pulm Circ. 2017 Oct-Dec;7(4):793-796. doi: 10.1177/2045893217732213. Epub 2017 Sep 15.
2
Hispanic Ethnicity and Social Determinants of Health in Pulmonary Arterial Hypertension: The Pulmonary Hypertension Association Registry.西班牙裔种族与肺动脉高压健康的社会决定因素：肺动脉高压协会登记研究
Ann Am Thorac Soc. 2022 Sep;19(9):1459-1468. doi: 10.1513/AnnalsATS.202109-1051OC.
3
Genetic Admixture and Survival in Diverse Populations with Pulmonary Arterial Hypertension.遗传混合与肺动脉高压患者的不同人群的生存。
Am J Respir Crit Care Med. 2020 Jun 1;201(11):1407-1415. doi: 10.1164/rccm.201907-1447OC.
4
Impact of race on survival in pulmonary arterial hypertension: Results from the REVEAL registry.种族对肺动脉高压患者生存的影响：REVEAL 注册研究结果。
J Heart Lung Transplant. 2020 Apr;39(4):321-330. doi: 10.1016/j.healun.2019.11.024. Epub 2020 Jan 24.
5
Racial/ethnic differences in hypertension and hypertension treatment and control in the multi-ethnic study of atherosclerosis (MESA).动脉粥样硬化多族裔研究（MESA）中高血压及高血压治疗与控制方面的种族/族裔差异。
Am J Hypertens. 2004 Oct;17(10):963-70. doi: 10.1016/j.amjhyper.2004.06.001.
6
Racial/ethnic disparities in medication use among veterans with hypertension and dementia: a national cohort study.高血压和痴呆症退伍军人用药方面的种族/族裔差异：一项全国队列研究。
Ann Pharmacother. 2009 Feb;43(2):185-93. doi: 10.1345/aph.1L368. Epub 2009 Feb 3.
7
Differences in the expression of DNA methyltransferases and demethylases in leukocytes and the severity of pulmonary arterial hypertension between ethnic groups.不同族群白细胞中 DNA 甲基转移酶和去甲基酶的表达差异与肺动脉高压严重程度的关系。
Physiol Rep. 2022 May;10(10):e15282. doi: 10.14814/phy2.15282.
8
Racial and Ethnic Differences in Pediatric Pulmonary Hypertension: An Analysis of the Pediatric Pulmonary Hypertension Network Registry.儿科肺动脉高压的种族和民族差异：儿科肺动脉高压网络注册分析。
J Pediatr. 2019 Aug;211:63-71.e6. doi: 10.1016/j.jpeds.2019.04.046. Epub 2019 Jun 5.
9
Racial/Ethnic Differences in Psychiatric and Medical Diagnoses Among Autistic Adults.成年自闭症患者精神科和医学诊断中的种族/民族差异。
Autism Adulthood. 2022 Dec 1;4(4):290-305. doi: 10.1089/aut.2021.0083. Epub 2022 Dec 13.
10
Racial-ethnic disparities in stroke care: the American experience: a statement for healthcare professionals from the American Heart Association/American Stroke Association.种族和民族差异在卒中护理中的表现：美国经验：美国心脏协会/美国卒中协会向医疗保健专业人员的声明。
Stroke. 2011 Jul;42(7):2091-116. doi: 10.1161/STR.0b013e3182213e24. Epub 2011 May 26.
引用本文的文献
1
Important Differences in Disease Severity, Echocardiography Findings, and Referral Delays in Non-Hispanic Black Patients With Pulmonary Arterial Hypertension.非西班牙裔黑人肺动脉高压患者在疾病严重程度、超声心动图检查结果及转诊延迟方面的重要差异
Pulm Circ. 2025 Jul 28;15(3):e70138. doi: 10.1002/pul2.70138. eCollection 2025 Jul.
2
Clinical characteristics, treatment patterns and healthcare resource utilisation for portopulmonary hypertension patients in the USA: a real-world study.美国门脉性肺动脉高压患者的临床特征、治疗模式及医疗资源利用情况：一项真实世界研究
BMJ Open. 2025 Jun 19;15(6):e089223. doi: 10.1136/bmjopen-2024-089223.
3
Validation of the Pulmonary Arterial Hypertension-Symptoms and Impact for Clinical Use (SYMPACT-CP): a qualitative interview study.肺动脉高压症状及临床应用影响评估（SYMPACT-CP）的验证：一项定性访谈研究
BMC Pulm Med. 2025 May 6;25(1):217. doi: 10.1186/s12890-025-03681-2.
4
Pulmonary arterial hypertension in Latin America. The age and comorbidity paradox.拉丁美洲的肺动脉高压。年龄与合并症悖论。
Int J Cardiol Congenit Heart Dis. 2025 Jan 31;19:100573. doi: 10.1016/j.ijcchd.2025.100573. eCollection 2025 Mar.
5
Demographic, hemodynamic characteristics, and therapeutic trends of pulmonary hypertension patients: The Pulmonary Hypertension Mexican registry (REMEHIP).肺动脉高压患者的人口统计学、血流动力学特征及治疗趋势：墨西哥肺动脉高压注册研究（REMEHIP）
Pulm Circ. 2024 Jun 17;14(2):e12395. doi: 10.1002/pul2.12395. eCollection 2024 Apr.
6
Macitentan in Pulmonary Arterial Hypertension Associated with Connective Tissue Disease (CTD-PAH): Real-World Evidence from the Combined OPUS/OrPHeUS Dataset.马昔腾坦治疗结缔组织病相关肺动脉高压（CTD-PAH）：来自OPUS/OrPHeUS联合数据集的真实世界证据
Cardiol Ther. 2024 Jun;13(2):315-339. doi: 10.1007/s40119-024-00361-w. Epub 2024 Mar 7.
7
Pulmonary Hypertension in Underrepresented Minorities: A Narrative Review.少数族裔中的肺动脉高压：一篇叙述性综述。
J Clin Med. 2024 Jan 4;13(1):285. doi: 10.3390/jcm13010285.
8
Long-term impact of add-on sequential triple combination therapy in pulmonary arterial hypertension: real world experience.肺动脉高压附加序贯三联疗法的长期影响：真实世界经验。
Ther Adv Respir Dis. 2023 Jan-Dec;17:17534666231199693. doi: 10.1177/17534666231199693.
9
Evolution and optimization of clinical trial endpoints and design in pulmonary arterial hypertension.肺动脉高压临床试验终点与设计的演变及优化
Pulm Circ. 2023 Aug 7;13(3):e12271. doi: 10.1002/pul2.12271. eCollection 2023 Jul.
10
is a candidate gene in sickle cell disease-associated pulmonary hypertension and pulmonary arterial hypertension.是镰状细胞病相关肺动脉高压和肺动脉高压中的一个候选基因。
Pulm Circ. 2023 Apr 1;13(2):e12227. doi: 10.1002/pul2.12227. eCollection 2023 Apr.
本文引用的文献
1
Selexipag for the Treatment of Pulmonary Arterial Hypertension.塞乐西帕用于肺动脉高压的治疗。
N Engl J Med. 2015 Dec 24;373(26):2522-33. doi: 10.1056/NEJMoa1503184.
2
Initial Use of Ambrisentan plus Tadalafil in Pulmonary Arterial Hypertension.初始使用安贝生坦联合他达拉非治疗肺动脉高压。
N Engl J Med. 2015 Aug 27;373(9):834-44. doi: 10.1056/NEJMoa1413687.
3
Gender and racial differences in nonalcoholic fatty liver disease.非酒精性脂肪性肝病中的性别和种族差异。
World J Hepatol. 2014 May 27;6(5):274-83. doi: 10.4254/wjh.v6.i5.274.
4
Macitentan and morbidity and mortality in pulmonary arterial hypertension.马西替坦治疗肺动脉高压的发病率和死亡率。
N Engl J Med. 2013 Aug 29;369(9):809-18. doi: 10.1056/NEJMoa1213917.
5
Riociguat for the treatment of pulmonary arterial hypertension.利奥西呱特治疗肺动脉高压。
N Engl J Med. 2013 Jul 25;369(4):330-40. doi: 10.1056/NEJMoa1209655.
6
Race and association with disease manifestations and mortality in scleroderma: a 20-year experience at the Johns Hopkins Scleroderma Center and review of the literature.种族与硬皮病的疾病表现及死亡率的关联：约翰·霍普金斯硬皮病中心20年经验及文献综述
Medicine (Baltimore). 2013 Jul;92(4):191-205. doi: 10.1097/MD.0b013e31829be125.
7
Epidemiology and sociodemographics of systemic lupus erythematosus and lupus nephritis among US adults with Medicaid coverage, 2000-2004.2000 - 2004年美国有医疗补助覆盖的成年人中系统性红斑狼疮和狼疮性肾炎的流行病学及社会人口统计学特征
Arthritis Rheum. 2013 Mar;65(3):753-63. doi: 10.1002/art.37795.
8
Race and sex differences in response to endothelin receptor antagonists for pulmonary arterial hypertension.种族和性别差异对肺动脉高压内皮素受体拮抗剂的反应。
Chest. 2012 Jan;141(1):20-26. doi: 10.1378/chest.11-0404. Epub 2011 Sep 22.
9
Pulmonary arterial hypertension: baseline characteristics from the REVEAL Registry.肺动脉高压：REVEAL 注册研究的基线特征。
Chest. 2010 Feb;137(2):376-87. doi: 10.1378/chest.09-1140. Epub 2009 Oct 16.
10
Increased mortality in African Americans with idiopathic pulmonary arterial hypertension.患有特发性肺动脉高压的非裔美国人死亡率增加。
J Natl Med Assoc. 2008 Jan;100(1):69-72. doi: 10.1016/s0027-9684(15)31177-9.
Zotero 插件